Incyte (INCY) Net Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Incyte (INCY) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 4.55% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 52.78% |
| 10 | Incyte | 25.61 Bn | 21.07 Bn | 1.57 Bn | 18.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.67% |
| Mar 31, 2026 | 68.83% |
| Dec 31, 2025 | 35.23% |
| Sep 30, 2025 | 25.31% |
| Jun 30, 2025 | -56.49% |
| Mar 31, 2025 | 8.53% |
| Dec 31, 2024 | 86.81% |
| Sep 30, 2024 | 15.99% |
| Jun 30, 2024 | -173.71% |
| Mar 31, 2024 | -5.75% |
| Dec 31, 2023 | -33.71% |
| Sep 30, 2023 | -17.87% |
| Jun 30, 2023 | 3.36% |
| Mar 31, 2023 | 45.17% |
| Dec 31, 2022 | 25.74% |
| Sep 30, 2022 | -3.87% |
| Jun 30, 2022 | 14.98% |
| Mar 31, 2022 | 13.66% |
| Dec 31, 2021 | 4.02% |
| Sep 30, 2021 | 3.38% |